PETACH TIKVA, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 15-17, 2022.

Barclays Global Investor Conference:

Following the live presentation, a replay of the presentation will be available under the Investor section of PolyPid’s website at https://investors.polypid.com/events-and-presentations/events and archived for 30 days thereafter. Investors interested in meeting with PolyPid during the conference should contact their Barclays representative.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD), is a phase 3 biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of abdominal and sternal surgical site infections (SSIs).
For additional Company information, please visit polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts: 
PolyPid, Ltd. 
Dikla Czaczkes Akselbrad
EVP & CFO
Tel: +972-747195700

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

Media Contact:
Nechama Feuerstein
551-444-0784
Nechama.Feuerstein@finnpartners.com

Source: PolyPid Ltd.